bioMerieux (OTCMKTS:BMXMF) Reaches New 12-Month Low – What’s Next?

Shares of bioMerieux (OTCMKTS:BMXMF) hit a new 52-week low during trading on Wednesday . The stock traded as low as $109.61 and last traded at $109.61, with a volume of 60 shares trading hands. The stock had previously closed at $110.62.

Analysts Set New Price Targets

Separately, BNP Paribas Exane downgraded shares of bioMerieux to a “neutral” rating in a report on Wednesday, January 28th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, bioMerieux has an average rating of “Hold”.

bioMerieux Stock Up 4.9%

The company has a current ratio of 2.27, a quick ratio of 1.30 and a debt-to-equity ratio of 0.08. The business’s fifty day simple moving average is $120.34 and its 200-day simple moving average is $127.91.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.